

**TOMAS OLSSON PUBLICATIONS 2017****Peer reviewed articles**

1. Alfredsson L, Hedstrom AK, Kockum I, Olsson T. Organic solvents and MS susceptibility; interaction with MS risk HLA genes. *Multiple Sclerosis Journal*. 2017;23(1):36-7.
2. Alfredsson L, Hedstrom AK, Strid P, Kockum I, Olsson T. The potency of the interaction between smoking and HLA MS risk genes depends on number of HLA risk alleles. *Multiple Sclerosis Journal*. 2017;23:51-.
3. Bedri SK, Fink K, Manouchehrinia A, Lundstrom W, Kockum I, Olsson T, et al. MS treatment effects on plasma cytokine receptor levels. *Multiple Sclerosis Journal*. 2017;23:299-300.
4. Bedri SK, Fink K, Manouchehrinia A, Lundstrom W, Kockum I, Olsson T, et al. MS treatment effects on plasma cytokine receptor levels. *Scandinavian Journal of Immunology*. 2017;86(4):293-.
5. Berglund R, Guerreiro-Cacais AO, Ruhrmann S, Hedreul MT, Khademi M, Jagodic M, et al. Autophagy associated pathways regulate degradation of myelin debris and microglial phenotypes to determine clinical outcome of neuroinflammation. *Scandinavian Journal of Immunology*. 2017;86(4):296-.
6. Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, et al. The Temporal retinal nerve Fiber layer Thickness is the Most important Optical coherence Tomography estimate in Multiple sclerosis. *Frontiers in Neurology*. 2017;8.
7. Bomfim IL, Lamb F, Fink K, Szakacs A, Silveira A, Franzen L, et al. The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction. *Genes and Immunity*. 2017;18(2):75-81.
8. Burkill S, Montgomery S, Hajiebrahimi M, Hillert J, Olsson T, Bahmanyar S. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. *Neurology*. 2017;89(6):555-62.
9. Cebers G, Alexander RC, Haerberlein SB, Han D, Goldwater R, Ereshefsky L, et al. AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. *Journal of Alzheimers Disease*. 2017;55(3):1039-53.
10. Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Manouchehrinia A. Course of disease of initially benign multiple sclerosis patients: long-term follow-up results of physical disability and cognitive impairment. *Multiple Sclerosis Journal*. 2017;23:61-.
11. Fernandes S, Morikawa H, Ewing E, Ruhrmann S, Karanathanasis N, Lagani V, et al. Understanding progression in multiple sclerosis through transcriptomics and DNA methylation in CD4+and CD8+T cells. *Multiple Sclerosis Journal*. 2017;23:189-90.

12. Forsberg L, Kagstrom S, Leandersson A, Berglund A, Hillert J, Nilsson P, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5). *Multiple Sclerosis Journal*. 2017;23:884-5.
13. Forsberg L, Leandersson A, Kagstrom S, Hillert J, Nilsson P, Dahle C, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4). *Multiple Sclerosis Journal*. 2017;23:635-6.
14. Frenken P, Hartung HP, Olsson T, Adams O, Warnke C. Type 0 blood group associates with higher anti-JCV antibody levels. *Multiple Sclerosis Journal*. 2017;23:918-9.
15. Gianfrancesco MA, Stridh P, Rhead B, Shao XR, Xu E, Graves JS, et al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. *Neurology*. 2017;88(17):1623-9.
16. Guerreiro-Cacais AO, Norin U, Gyllenberg A, Berglund R, Beyeen AD, Petit-Teixeira E, et al. VAV1 regulates experimental autoimmune arthritis and is associated with anti-CCP negative rheumatoid arthritis. *Genes and Immunity*. 2017;18(1):48-56.
17. Hedstrom AK, Katsoulis M, Hossjer O, Bomfim IL, Oturai A, Sondergaard HB, et al. The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. *European Journal of Epidemiology*. 2017;32(10):909-19.
18. Hossjer O, Alfredsson L, Hedstrom AK, Lekman M, Kockum I, Olsson T. Quantifying and estimating additive measures of interaction from case-control data. *Modern Stochastics-Theory and Applications*. 2017;4(2):109-25.
19. Iacobaeus E, Douagi I, Jitschin R, Andren AT, Gavin C, Lefsihane K, et al. Functional shift of myeloid-derived suppressor cells during Multiple Sclerosis disease course. *Scandinavian Journal of Immunology*. 2017;86(4):335-.
20. Kagstrom S, Leandersson A, Forsberg L, Berglund A, Hillert J, Nilsson P, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of natalizumab (IMSE 1). *Multiple Sclerosis Journal*. 2017;23:365-6.
21. Kagstrom S, Leandersson A, Forsberg L, Berglund A, Hillert J, Nilsson P, et al. Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile. *Multiple Sclerosis Journal*. 2017;23:626-7.
22. Kavaliunas A, Karrenbauer VD, Tinghog P, Friberg E, Olsson T, Alexanderson K, et al. Cognitive function predicts work disability among multiple sclerosis patients. *Multiple Sclerosis Journal*. 2017;23:479-80.
23. Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta I, et al. Dynamics and heterogeneity of brain damage in multiple sclerosis. *Plos Computational Biology*. 2017;13(10).
24. Leandersson A, Kagstrom S, Forsberg L, Hillert J, Nilsson P, Dahle C, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2). *Multiple Sclerosis Journal*. 2017;23:374-5.

25. Leandersson A, Kagstrom S, Forsberg L, Hillert J, Nilsson P, Dahle C, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). *Multiple Sclerosis Journal*. 2017;23:888-9.
26. Lind A, Freyhult E, Ramelius A, Olsson T, Arnheim-Dahlstrom L, Lamb F, et al. Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. *Viral Immunology*. 2017;30(8):590-600.
27. Lindahl H, Martini E, Brauner S, Nikamo P, Serezal IG, Guerreiro-Cacais AO, et al. IL-22 binding protein regulates murine skin inflammation. *Experimental Dermatology*. 2017;26(5):444-6.
28. Linden M, Sepulveda JIR, James T, Thorlacius GE, Brauner S, Gomez-Cabrero D, et al. Sex influences eQTL effects of SLE and Sjogren's syndrome-associated genetic polymorphisms. *Biology of Sex Differences*. 2017;8.
29. Marabita F, Almgren M, Sjöholm LK, Kular L, Liu Y, James T, et al. Smoking induces DNA methylation changes in Multiple Sclerosis patients with exposure-response relationship. *Scientific Reports*. 2017;7.
30. Montgomery S, Hiyoshi A, Burkill S, Alfredsson L, Bahmanyar S, Olsson T. Concussion in adolescence and risk of multiple sclerosis. *Annals of Neurology*. 2017;82(4):554-61.
31. Montgomery S, Hiyoshi A, Burkill S, Alfredsson L, Bahmanyar S, Olsson T. Reply to "Concussion May Not Cause Multiple Sclerosis". *Annals of Neurology*. 2017;82(4):652-3.
32. Morgan RA, Beck KR, Nixon M, Homer NZM, Crawford AA, Melchers D, et al. Carbonyl reductase 1 catalyzes 20 beta-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity. *Scientific Reports*. 2017;7.
33. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmstrom C, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. *Journal of Neurochemistry*. 2017;141(2):296-304.
34. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmstrom C, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. *Multiple Sclerosis Journal*. 2017;23(1):62-71.
35. Novakova L, Zetterberg H, Axelsson M, Sundstrom P, Khademi M, Gunnarsson M, et al. Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response. *European Journal of Neurology*. 2017;24:577-.
36. Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. *Neurology*. 2017;89(22):2230-7.

37. Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, et al. Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. *Npj Genomic Medicine*. 2017;2.
38. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nature Reviews Neurology*. 2017;13(1):25-36.
39. Olsson T, Hedstrom AK, Oturai A, Harbo H, Barcellos L, Hillert J, et al. The interaction between smoking and HLA genes in multiple sclerosis; replication and refinement. *Multiple Sclerosis Journal*. 2017;23(1):37-.
40. Olsson T, Montgomery S, Hiyosh A, Alfredsson L, Bahmanyar S. Concussion in adolescence and multiple sclerosis risk. *Multiple Sclerosis Journal*. 2017;23:122-3.
41. Romania P, Cifaldi L, Pignoloni B, Starc N, D'Alicandro V, Melaiu O, et al. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immuno-evasion. *Cell Reports*. 2017;20(4):846-53.
42. Rosjo E, Lossius A, Abdelmagid N, Lindstrom JC, Kampman MT, Jorgensen L, et al. Effect of high-dose vitamin D-3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*. 2017;23(3):395-402.
43. Sorce S, Stocker R, Seredenina T, Holmdahl R, Aguzzi A, Chio A, et al. NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence? *Free Radical Biology and Medicine*. 2017;112:387-96.
44. Steri M, Orru V, Idda ML, Pitzalis M, Pala M, Zara I, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. *New England Journal of Medicine*. 2017;376(17):1615-26.
45. Yau ACY, Piehl F, Olsson T, Holmdahl R. Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases. *Immunology*. 2017;150(4):408-17.